Published in J Clin Oncol on April 20, 2007
MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst (2010) 1.29
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta (2012) 1.22
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol (2009) 1.09
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis (2012) 1.04
Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer (2008) 1.01
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS One (2009) 0.86
DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol (2012) 0.81
Double-labelling immunohistochemistry for MGMT and a "cocktail" of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours. Acta Neuropathol Commun (2013) 0.78
A peptide & peptide nucleic acid synthesis technology for transporter molecules and theranostics--the SPPS. Int J Med Sci (2014) 0.77
The fallacy of single-agent chemotherapy for cancer. J Clin Oncol (2007) 0.76
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res (2009) 0.75
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn (2008) 2.71
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.26
Current concepts and management of glioblastoma. Ann Neurol (2011) 2.23
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Phase II study of imatinib in advanced chordoma. J Clin Oncol (2012) 1.89
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol (2012) 1.68
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res (2006) 1.67
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol (2003) 1.50
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol (2008) 1.45
DNA fingerprinting of glioma cell lines and considerations on similarity measurements. Neuro Oncol (2012) 1.44
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol (2002) 1.44
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol (2010) 1.44
Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model. Ann Thorac Surg (2006) 1.42
Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol (2013) 1.37
Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep (2005) 1.36
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol (2010) 1.32
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res (2008) 1.32
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 1.31
Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med (2012) 1.27
Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer (2006) 1.24
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol (2012) 1.22
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care (2006) 1.21
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One (2009) 1.19
Optimal management of elderly patients with glioblastoma. Cancer Treat Rev (2012) 1.17
Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer (2009) 1.16
Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol (2010) 1.16
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol (2009) 1.15
The role of radio- and chemotherapy in glioblastoma. Onkologie (2005) 1.14
Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res (2009) 1.13
Integrin inhibitors reaching the clinic. J Clin Oncol (2007) 1.12
Targeting integrins in malignant glioma. Target Oncol (2010) 1.11
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol (2011) 1.10
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol (2013) 1.08
The accuracy of predicting survival in individual patients with cancer. J Neurosurg (2013) 1.08
Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J (2012) 1.08
Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol (2010) 1.08
Epilepsy in brain tumor patients. Curr Opin Neurol (2010) 1.07
A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol (2008) 1.04
Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol (2012) 1.03
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer (2009) 1.03
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res (2010) 1.02
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol (2011) 1.02
Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther (2006) 1.02
Growth promoting signaling by tenascin-C [corrected]. Cancer Res (2004) 0.99
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer (2008) 0.99
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus (2006) 0.99
MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers (2007) 0.98
MGMT promoter methylation in malignant gliomas. Target Oncol (2010) 0.97
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. Radiother Oncol (2010) 0.96
Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer (2014) 0.95
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer (2008) 0.94
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? Oncologist (2013) 0.93
Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res (2007) 0.93